Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03730051 · ClinicalTrials.gov registry record · Phase 4
Dotarem vs Gadobutrol Contrast for Breast MRI
A Phase 4 study of Breast Diseases, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03730051 is a Phase 4 study of Breast Diseases that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 300 participants, roughly in line with the 280-participant average among 8 other Breast Diseases trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03730051, a Phase 4 study of Breast Diseases, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
In this randomized clinical trial, the investigators expect to demonstrate that the MRI contrast agent Dotarem is not less effective in contrast enhancement of breast lesions then Gadavist. Participants will be randomized to receive either Dotarem or Gadavist. In all cases, inclusion criteria will require patients having undergone or scheduled or most likely to be scheduled to undergo tissue sampling with histology results available. The patients will be prospectively and consecutively identified such that the majority of patients included will have been diagnosed with breast cancer, while including benign disease in the minority of patients in each arm. Following randomized enrollment, quantitative, semi-quantitative and qualitative image analysis will be performed to objectively assess for differences in image quality and diagnostic value.
Conditions Studied
Interventions
- DRUG Gadobutrol
- DRUG Gadoterate meglumine
Study Locations (1)
Massachusetts
- UMass Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03730051
The ClinicalTrials.gov registry entry for NCT03730051 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 280-participant average among 8 other Breast Diseases trials with a reported enrollment target. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Diseases appearing as the primary indexed condition, and to 2 interventions - of which Gadobutrol is the first listed.
NCT03730051 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03730051 about?
NCT03730051 is a clinical study titled "Dotarem vs Gadobutrol Contrast for Breast MRI". In this randomized clinical trial, the investigators expect to demonstrate that the MRI contrast agent Dotarem is not less effective in contrast enhancement of breast lesions then Gadavist. Participants will be randomized to receive either Dotarem or Gadavist. In all cases, inclusion criteria will r...
What is the current status of trial NCT03730051?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2021-03-01. Estimated completion is 2025-12-31.
What conditions does trial NCT03730051 study?
This clinical trial studies the following conditions: Breast Diseases.
What interventions are being tested in trial NCT03730051?
The interventions under investigation include: Gadobutrol (DRUG), Gadoterate meglumine (DRUG).
Who is sponsoring clinical trial NCT03730051?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03730051 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
RECRUITING
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
ACTIVE NOT RECRUITING · Phase 1
-
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
ACTIVE NOT RECRUITING
-
Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.